In addition to underscoring the pivotal role of CD8+ T cells in mediating tumor control, CD47 × PD‐L1 BisAb treatment outperformed anti‐PD‐L1 monotherapy in generating highly functional CD8+ TIL, demonstrating the cumulative advantage of reinvigorating adaptive immune responses by disrupting innate inhibitory pathways. Here, CD47 is linked to neoplasm.